$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
艾乐替尼治疗肺癌脑转移疗效显著
2025-10-19 11:44:20
Check Details
奥希替尼的耐药机制与耐药原因
2025-10-19 11:44:20
Check Details
克唑替尼ROS1阳性的晚期非小细胞肺癌靶向药
2025-10-19 11:44:20
Check Details
色瑞替尼第二代ALK抑制剂
2025-10-19 11:44:20
Check Details
克唑替尼可延长ALK阳性非小细胞肺癌总生存时间
2025-10-19 11:44:20
Check Details
色瑞替尼ALK阳性非小细胞肺癌一线用药
2025-10-19 11:44:20
Check Details
赛可瑞对NSCLC有显著的抗肿瘤作用
2025-10-19 11:44:20
Check Details
易瑞沙耐药的患者可以服用奥希替尼
2025-10-19 11:44:20
Check Details
艾乐替尼治疗肺癌有效率高达92%
2025-10-19 11:44:20
Check Details
卡博替尼(Cabozantinib)在治疗肺癌应用很广泛
2025-10-19 11:44:20
Check Details
吉非替尼作为晚期非小细胞肺癌一线治疗的II期临床试验
2025-10-19 11:44:20
Check Details
胃肠道不好的患者,如何服用吉非替尼?
2025-10-19 11:44:20
Check Details
1
2
...
2995
2996
2997
2998
2999
3000
3001
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
2
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
3
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
4
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
5
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
6
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
7
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
8
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
9
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor